As Novo Nordisk and Pfizer vie for control of Metsera, a new round of takeout proposals has resulted in the obesity biotech declaring Novo's offer "superior"—even though it has already inked an ...

Amid Novo Nordisk and Pfizer’s whiplash contest for obesity biotech Metsera, Novo’s CEO has, quite literally, told his company's rival to put its money where its mouth is. “Novo Nordisk and Pfizer ...

Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market served by Alnylam Pharmaceuticals, BridgeBio and Pfizer. The phase 2 trial compared two doses of ...

Editor's note: This article has been updated to provide clarity on a head-to-head study Eli Lilly conducted on its candidate, orforglipron. A pill version under development of Novo Nordisk's (NVO) GLP ...

(Bloomberg) --Lars Rebien Sorensen is back as chairman of Novo Nordisk A/S following a shareholder meeting that exposed the depth of rivalry between the Danish drugmaker and US arch nemesis Pfizer Inc ...

Novo Nordisk’s CEO won’t comment on whether the Danish company will go even higher in its bidding war for Metsera but said the Big Pharma “feels this deal will be closed.” Last week brought the ...

Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness to compete on price as it tries to claw back a larger share of the US market ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit and sales forecasts again on Wednesday, in an early blow to its new CEO as the Danish drugmaker battles to claw back lost ...

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat diabetes, could help trim their ...

NEW YORK/LONDON, Nov 12 (Reuters) - When Novo Nordisk (NOVOb.CO), opens new tab CEO Mike Doustdar learned in late September that Metsera had accepted a $7.3 billion rival bid from Pfizer (PFE.N), ...

For Novo Nordisk, the retreat wasn't weaknessit was discipline. Management said over the weekend that it wouldn't raise its offer, standing by a commitment to financial discipline and shareholder ...

NEW YORK, Nov 6 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab CEO Mike Doustdar said during a White House event on Thursday that the company's bid for obesity biotech Metsera is higher than the ...